Announced Tue, 28 Apr · 14:48 IST

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.3%1-day move
₹2052.00
prior close
₹2100.05
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-0.5-0.0-0.0+2.3+9.2+19.3+23.0+17.9+17.0+17.9+20.0+33.2
Up moveDown movePending
AI summary

Fredun Pharmaceuticals has filed an initial disclosure with BSE under SEBI's Large Corporate framework, a mandatory submission for companies whose outstanding borrowings exceed prescribed thresholds. The disclosure typically includes details on the company's total borrowings, credit rating, and planned actions to meet SEBI norms on green and sustainability-linked debt. The full table contents from the original BSE filing page were not accessible at the time of analysis, so specific numbers and reported figures cannot be confirmed. This is a periodic, compliance-driven submission rather than a strategic announcement.

Likely market impact

This is a routine regulatory filing with no direct material impact on the stock price. It does, however, confirm that Fredun Pharmaceuticals' borrowings place it in the 'Large Corporate' category, meaning it will be subject to ongoing SEBI green-debt and disclosure obligations going forward.